Agaplesion Frankfurter Diakonie Kliniken gGmbH

At Agaplesion Frankfurter Diakonie Kliniken gGmbH in Frankfurt, clinical studies in gynecology and obstetrics focus on neoplasms, with a strong emphasis on breast cancer and related breast neoplasms. The trials are designed to assess new treatment approaches and improve outcomes for people with early and advanced disease.

• Studying HER2-positive, hormone receptor-positive early breast cancer to see whether adding new targeted therapy can improve response.
• Evaluating endocrine therapy strategies for ER-positive, HER2-negative early breast cancer in patients at higher risk of recurrence.
• Investigating advanced HER2-negative, hormone receptor-positive breast cancer to better understand treatment effectiveness and disease control.

Overall, the site contributes to research on targeted therapy, endocrine treatment, and outcomes in breast cancer, aiming to refine care for patients across different stages of the disease.

The research portfolio includes trials centered on breast cancer, especially early-stage disease and cases with a higher chance of recurrence. These studies are exploring ways to improve treatment effectiveness and long-term disease control through better use of hormonal and targeted therapies.

• Testing whether new combinations can increase response rates in HER2-positive, PIK3CA-mutant early breast cancer.
• Comparing a new endocrine therapy option with standard care after initial treatment for early breast cancer.
• Examining patterns of benefit and resistance in advanced breast cancer to support more personalized treatment choices.

These studies reflect a broader effort to improve both treatment response and survival outcomes for patients with breast neoplasms.

Research at this site also includes studies in advanced breast cancer, particularly HER2-negative, hormone receptor-positive disease. The goal is to evaluate how well current and emerging therapies work in the first-line setting and to better understand patterns linked to response and resistance.

• Assessing treatment effectiveness in advanced HER2-negative, HR-positive breast cancer.
• Exploring molecular and clinical factors that may influence benefit from therapy.
• Supporting more informed decisions for patients with metastatic or advanced disease.

This work helps advance knowledge of oncology care by focusing on better disease control, durability of benefit, and more tailored treatment approaches.